Sarah Cannon Research UK
Sarah Cannon Research UK is a unique standalone trial facility that collaborates and works closely with clinical investigators to develop new and innovative cancer therapies for patients.
Sarah Cannon Research UK is part of the Hospital Corporation of America (HCA) network, which comprises six central London hospitals and an expert group of 60 oncologists making up our Leaders in Oncology Care (LOC). We specialise in the development of novel cancer therapies and provide a clinical research option for cancer patients in London and the United Kingdom.
Sarah Cannon Research UK is the first trials unit outside the NHS that has the ability to offer new anti-cancer drugs in clinical trials. As a dedicated trials unit we are focused on fast study set-up time lines to offer patients rapid access to new investigational drug therapies – importantly we are open for both private and NHS patients.